Shopping Cart 0
Cart Subtotal
USD 0

Mylan NV (MYL) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV (MYL)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Mylan NV, Medical Equipment, Deal Details 11

Venture Financing 11

Zyomyx Raises USD 6 Million In First Closing Of Series 2 Preferred Financing 11

Partnerships 12

Mylan Teoranta Enters into Licensing Agreement with Contura 12

Mylan Enters into Partnership with Atomo Diagnostics 13

Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17

Debt Offering 18

Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18

Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19

Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24

Acquisition 25

Mylan Acquires Meda for USD9.42 Billion 25

Mylan NV-Key Competitors 27

Mylan NV-Key Employees 28

Mylan NV-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 36

Strategy And Business Planning 36

Sep 25, 2018: Mylan signs HIV test commercialisation deal with Atomo Diagnostics 36

Financial Announcements 37

Aug 08, 2018: Mylan reports second quarter 2018 results and updates 2018 guidance 37

May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 42

Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 44

Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 46

Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 48

May 10, 2017: Mylan Reports First Quarter 2017 Results 52

Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 54

Corporate Communications 56

May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 56

Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 58

Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 59

May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 60

Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 61

Legal and Regulatory 62

Jun 28, 2018: Mylan Statement: Morgantown Operations 62

Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 63

Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 64

Product News 65

Apr 11, 2018: Investor Day Highlights Durability of Mylan's Global Platform 65

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Mylan NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Mylan NV, Medical Equipment, Key Facts, 2017 2

Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Mylan NV, Deals By Market, 2012 to YTD 2018 9

Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Zyomyx Raises USD 6 Million In First Closing Of Series 2 Preferred Financing 11

Mylan Teoranta Enters into Licensing Agreement with Contura 12

Mylan Enters into Partnership with Atomo Diagnostics 13

Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17

Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18

Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19

Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24

Mylan Acquires Meda for USD9.42 Billion 25

Mylan NV, Key Competitors 27

Mylan NV, Key Employees 28

Mylan NV, Other Locations 29

Mylan NV, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Mylan NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.